By Cocer Peptides 
1 ọnwa gara aga
Edemede na ozi ngwaahịa niile enyere na webụsaịtị a bụ naanị maka mgbasa ozi na ebumnuche mmụta.
Ngwaahịa ndị enyere na webụsaịtị a bụ naanị maka nyocha in vitro. A na-eme nyocha in vitro (Latin: * na iko *, nke pụtara na ihe eji enyo) na mpụga ahụ mmadụ. Ngwaahịa ndị a abụghị ọgwụ, ndị US Food and Drug Administration (FDA) akwadoghị ya, ha agaghịkwa eji ya gbochie, gwọọ, ma ọ bụ gwọọ ọnọdụ ahụike ọ bụla, ọrịa, ma ọ bụ ọrịa. Iwu amachibidoro nke ọma iwebata ngwaahịa ndị a n'ime ahụ mmadụ ma ọ bụ anụmanụ n'ụdị ọ bụla.
Nchịkọta
Tirzepatid, ọgwụ ọhụrụ, enwetala nlebara anya dị ukwuu na ngalaba ọgwụgwọ ọrịa shuga. Ọ bụ agonist nke mbụ n'ụwa nke glucagon-dị ka peptide-1 (GLP-1) nnabata yana nnabata insulinotropic polypeptide (GIP) dabere na glucose. Site na usoro omume ya pụrụ iche, ọ na-eṅomi mmetụta okike nke GLP-1 na GIP, na-enye nhọrọ ọhụrụ maka njikwa glucose ọbara.
Ọgụgụ 1 Usoro ọrụ Tirzepatid n'ime ahụ mmadụ.
Usoro nke Omume
Iwu nke insulin na glucagon secretion: Tirzepatid na-abawanye mmepụta insulin ma na-ebelata ntọhapụ glucagon n'ụzọ dabere na glucose. Mgbe ọkwa glucose ọbara na-ebili, Tirzepatid na-akpali mkpụrụ ndụ beta nke pancreatic ka ọ mepụta insulin karịa, si otú a na-eme ka nnabata glucose na-arụ ọrụ ngwa ngwa ma na-ebelata ọkwa glucose ọbara; ọ na-egbochikwa nzuzo nke glucagon, na-ebelata mmepụta glucose imeju, na-eme ka ọkwa glucose dị n'ọbara kwụsie ike. Usoro nhazi usoro ihe abụọ a na-enyere aka ịnọgide na-enwe nguzozi glucose ọbara dị ike, na-ebelata nke ọma ma ibu ọnụ na ọkwa glucose ọbara mgbe nri gasịrị.
Ịkwalite satiety na ọnwụ dị arọ: Ọgwụ a nwere ike ịkwalite satiety, na-eduga ndị ọrịa iji belata nri oriri ma si otú ahụ felata. Mbelata ibu dị oke mkpa maka ndị ọrịa nwere ụdị ọrịa shuga 2, ebe oke ibu na-ejikọkarị ya na nguzogide insulin. Site n'ibelata ibu, Tirzepatid na-enyere aka melite mmetụta insulin, na-eme ka ahụ dịkwuo mma na insulin ma si otú a na-achịkwa ọkwa glucose ọbara nke ọma. Na mgbakwunye, mbelata ibu na-enyere aka belata ihe ize ndụ nke nsogbu dị ka ọrịa obi na ndị ọrịa shuga.
Na-egbu oge mkpofu gastric: Tirzepatid na-egbu oge ịwụsa afọ, na-agbatị oge nri na-adị n'ime afọ ma na-ebelata ịbanye n'ime eriri afọ, si otú ahụ na-egbochi mmụba ngwa ngwa na ọkwa shuga ọbara. Mmetụta a na-enyere aka mee ka mgbanwe shuga dị n'ọbara kwụsie ike, ọkachasị site n'ịchịkwa ọnụ ọnụ shuga dị n'ọbara postprandial nke ọma, na-eke ọnọdụ dị mma maka njikwa shuga ọbara kwụsiri ike.
Imeziwanye ihe nrịbama metabolic: Na mgbakwunye na mmetụta ya na shuga ọbara na ịdị arọ, Tirzepatid na-egosipụtakwa mmetụta dị mma n'ịkwalite ọkwa lipid na ihe nrịbama metabolic ndị ọzọ. Nnyocha ụlọ ọgwụ na-egosi na ọ na-enyere aka belata ọkwa nke lipoprotein dị ala (LDL) na triglyceride, na-eme ka ahụike metabolic n'ozuzu ya dịkwuo elu ma na-ebelata ohere nke ọrịa obi na ndị na-arịa ọrịa shuga.
Ngwa
N'ime SURPASS zuru ezu na SURMOUNT ọmụmụ ụlọ ọgwụ buru ibu nke Atọ, Tirzepatid gosipụtara arụmọrụ njikwa glucose ọbara dị elu. E jiri ya tụnyere placebo, Tirzepatid belatara ọkwa haemoglobin A1c (HbA1c) nke ukwuu ma na-egosipụtakwa mmetụta mbelata ibu dị mma. Ịrụ ọrụ ya karịrị nke ndị agonists nnabata GLP-1 akwadoro ugbu a. N'ime ule ụfọdụ, ndị ọrịa a na-agwọ Tirzepatid nwere mbelata nke ukwuu na ọkwa HbA1c na mbelata ibu karịa, na-egosipụta n'ụzọ doro anya ịdị irè ya na ogo ya na njikwa glycemic na njikwa ibu.
Ọgwụgwọ nke ụdị ọrịa shuga 2: Dị ka ihe mgbakwunye nri na mmega ahụ, Tirzepatid na-enye nhọrọ ọgwụgwọ dị mma maka ndị ọrịa nwere ụdị ọrịa shuga 2. Ma ejiri ya dị ka monotherapy ma ọ bụ yana yana ọgwụ antidiabetic ndị ọzọ, Tirzepatid na-eme ka njikwa glucose dị n'ọbara nke ndị ọrịa dịkwuo mma.
Mmechi
Na nchịkọta, Tirzepatid na-egosipụta uru dị na njikwa glucose ọbara n'ihi usoro ya pụrụ iche na arụmọrụ ya na nnwale ụlọ ọgwụ. Ọ bụghị naanị na ọ na-ebelata ọkwa glucose ọbara n'ụzọ dị irè kamakwa ọ na-ekerekwa òkè dị mma n'ịchịkwa ibu na imezi ihe nrịbama metabolic.
Isi mmalite
[1] Sood A, Kaur P, Syed O, et al. Ịgbanwe nlekọta ọrịa shuga: ikpughe ikike tirzepatide na njikwa glycemic na karịa [J]. Nyocha ọkachamara nke Clinical Pharmacology, 2024,17 (3): 235-246.DOI: 10.1080/17512433.2024.2310070.
[2] Wong E, Cope R, Dima L, et al. Tirzepatid: A Dual Glucose-based Insulinotropic Polypeptide na Glucagon-dị ka Peptide-1 Agonist maka njikwa nke ụdị 2 ọrịa shuga mellitus[J]. Akwụkwọ akụkọ American Therapeutics, 2023,30 (1): e26-e35.DOI: 10.1097/MJT.0000000000001588.
[3] Kumar D, Harshidha D, Mousigan M, et al. Nkọwa na Tirzepatid, Ọgwụgwọ Abụọ Ezubere maka Ọrịa shuga na oke ibu [J]. Akwụkwọ akụkọ mba ụwa nke nyocha ọhụụ na uto, 2022,7:983.DOI:10.5281/zenodo.7420605.
[4] Chavda VP, Ajabiya J, Teli D, et al. Tirzepatid, Oge Ọhụrụ nke ọgwụgwọ abụọ ezubere iche maka ọrịa shuga na oke ibu: Ntụle Obere[J]. Molecules, 2022,27(13).DOI:10.3390/molecules27134315.
[5] Forzano I, Varzideh F, Avisato R, et al. Tirzepatid: Mmelite usoro[J]. Akwụkwọ akụkọ International nke Science Molecular, 2022,23 (23) .DOI: 10.3390/ijms232314631.
Ngwaahịa dị maka naanị nyocha:
